Larry Watt, Pharmd, Mba Email & Phone Number

Root, Switzerland, Ch

Served as scientific lead for company’s GI oncology portfolio, including pancreatic, hepatocellular and gastric cancers. Performed and provided input to wide range of study start-up / close-out activities: Protocol development, medical monitoring planning, ICF, site selection, eCRF build, SIV, risk management planning, and data cleaning. Led regional team of 5 CRSs; developed operational strategies to achieve organizational goals and improved business processes. Mentored new hires and conducted annual performance evaluation.• Co-led 2 PhIII trials of Tumor-Treating Fields in patients with locally advanced pancreatic cancer (PANOVA-3) and brain mets (METIS); drove cross-functional and global collaborations, successfully meeting recruitment goals• Devised strategic engagement plans targeting medical / radiation oncologists and surgeons, significantly shortening enrollment window and improving screening efficiency across 30+ academic and community sites in North America and Asia• Collaborated with internal and external stakeholders to promptly revolve site queries, including responses to IRBs; conducted thorough medical and safety monitoring, ensuring high data integrity and strict compliance with regulatory standards• Assessed and led study progress reporting to Swissmedic; addressed queries from FDA related to past safety reports, resulting in all submissions being accepted without revision• Analyzed protocol deviation trends and implemented targeted remedial training with site staff, resulting in significantly improved compliance and reduced deviation rates• Co-led data cleaning initiatives for PANOVA-3 using EDC tools such as RAVE; meticulously reviewed over 200 patient profiles, identifying and revolving discrepancies to ensure accuracy and reliability of clinical trial data• Contributed to preparation of study reports by optimizing presentation of TLFs; developed pipeline portfolio content to strengthen partnerships with investigators and collaborators

Rahway, New Jersey, Us

Served as Esophageal / Pancreatic Tumor Lead (Subject Matter Expert) on RMSD Field Team. Supported one of the largest investigator-initiated study (IIS) programs in oncology from AOI alignment, study design assessment, trial conduct to manuscript publication. Forged strong partnership with leading cancer research institutions.• Supported approximately 10 company-sponsored trials, 20 IISs in oncology and LCM activities of 4 approved compounds• Served as Protocol Lead for 3 PhIII studies; generated potential site lists; presented and participated in advisory boards to identify and mitigate challenges ahead of protocol implementation, ensuing smooth trial execution• Pioneered insights app installed as dashboard tool for easy access on iPads, facilitating SWOT analysis and empowering internal stakeholders to make informed business, strategic decisions• Identified and capitalized on opportunities to connect MRL scientists to investigators and KOLs, fostering scientific collaboration and advancing research and innovation efforts • Delivered deep-dive presentations on latest trial data to senior leadership at major scientific congresses, influencing formulation of effective medical and clinical development strategies

Summit, New Jersey, Us

Facilitated communication and exchange of scientific and clinical information with HCPs. Provided product training to internal teams. Collaborated with investigators to support development and implementation of IISs and company-sponsored trials. Executed local / national educational initiatives across diverse audiences, including KOLs, HCPs, nurses, and patient advocates.• Provided critical scientific support for successful launches of Abraxane® in metastatic pancreatic cancer and NSCLC• Participated in formulary discussions with key accounts to address business needs, resulting in removal of restriction on Abraxane®’s usage for mPDAC indication• Supported first immunotherapy trial with Keytruda® and Abraxane® in company’s history of IIS program from concept to activation, addressing data gap for NSCLC indication• Led field efforts in organizing regional consultant panels from event planning, content development to group facilitation, raising product / pipeline awareness and collecting fresh insights to meet established goals and strategic initiatives• Planned and coordinated corporate visit to 2 NCCN institutions (Northwestern and Michigan), facilitating knowledge exchange, exploring opportunities for research collaboration, and sharing insights for innovative solutions

Paris, France, Fr

Collaborated cross-functionally formulating robust territory plans to maximize engagement opportunities with therapeutic thought leaders. Facilitated strategic partnership with NCI Cooperative Groups. Assessed merits of educational grant proposals to ensure alignment with industry standards and company's strategic objectives.• Implemented series of local educational initiatives targeting prostate cancer specialists around Jevtana® launch; spearheaded KOL mapping project to identify and engage clinician advocates• Executed launch of oral fludarabine in CLL; developed slide presentation on key differentiation factors, including unique pharmacokinetic profile, convenience and patient compliance• Served as captain for 2 advisory boards to better understand current treatment landscape of rectal cancer and practice variations across regions within US; synthesized feedback and presented key takeaways to senior leadership• Managed collaboration with Alliance (formerly CALGB), facilitating overall cooperative group strategy including coordination of pre-launch activity for aflibercept to accelerate drug's market readiness

Doctor Of Pharmacy (Pharm.D.)

Master Of Business Administration (Mba), Finance, Marketing, Healthcare Management

Bs, Animal Physiology